Sotera Health

Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sotera Health reports solid Q4 growth, cautious outlook for 2023

Sotera Health delivered growth in Q4 2022, closed a major litigation settlement, and outlined a cautious outlook for 2023. Strategic investments in EO enhancements and pharma growth signal long-term vision, while challenges in revenue and adjusted EPS are acknowledged. Overall, the company remains optimistic about future growth prospects.

Sotera Health reports Q1 revenue decline, eyes growth opportunities

Sotera Health faced revenue and EBITDA declines in Q1 2023 but remains optimistic about future growth prospects.
The company is addressing challenges in inflation, labor, and supply chains while focusing on operational improvements.
Opportunities for revenue growth exist through Nordion volumes, facility enhancements, and regulatory compliance efforts.
Overall, Sotera Health's performance reflects a mix of challenges, strengths, and opportunities for strategic advancement.

Sotera Health releases settlement funds, faces revenue declines in Q2

Sotera Health navigated challenges in Q2 2023 with declines in revenues and adjusted EBITDA but showcased strengths in strategic planning and operational efficiency.
The company's outlook remains positive, with opportunities for growth through capacity expansions and improved volumes in the second half of the year.
Addressing challenges in revenue performance and customer inventory levels will be crucial for sustaining growth and investor confidence.
Proactive measures and transparent communication underscore Sotera Health's commitment to navigating market uncertainties and driving long-term success.

Sotera Health reports revenue growth amidst challenges and opportunities

Sotera Health (SHC) delivered a mixed performance in Q3 2023 with revenue growth, margin improvement, and operational challenges.
The company maintains a strong liquidity position and is actively managing its financial metrics to drive long-term growth.
While facing challenges from external factors, Sotera Health (SHC) has opportunities to enhance efficiency and capitalize on growth prospects.

Sotera Health (SHC) posts robust Q4 results, eyes 2024 growth

Sotera Health (SHC) delivered strong financial performance in Q4 2023 and full year.
Operational achievements and resolved litigation bolstered the company's position.
Challenges include potential impact on revenue growth from Nordion contracts.
Optimistic outlook for 2024 with a focus on customer value and safety.

Sotera Health (SHC) reports robust Q1 performance and growth outlook

Sotera Health (SHC) delivered strong Q1 2024 results, reaffirming growth outlook and showcasing financial resilience.
Management's confidence in defense against lawsuits and compliance with regulations, alongside strategic investments, underpin the company's stability and growth potential.
With a focus on operational efficiency, capacity expansions, and investor engagement, Sotera Health (SHC) is poised for sustainable growth and value creation.

Sotera Health posts robust Q2 results, eyes efficiency and growth

Sotera Health delivered strong financial results in Q2 2024, supported by revenue growth and operational improvements across key segments.
Despite challenges such as FX headwinds and macroeconomic uncertainties, the company's solid liquidity position and debt refinancing strengthen its financial foundation.
Opportunities lie in optimizing cash flow, managing capital expenditures, and leveraging new board expertise for sustained growth and value creation.

Sotera Health reports robust Q3 growth, affirms 2024 outlook

Sotera Health's Q3 2024 performance reflects strong revenue and EBITDA growth across key business segments, underlining operational efficiency and market demand.
While facing challenges in regulatory compliance and market dynamics, the company's diverse strengths in critical sectors and upcoming Investor Day signal resilience and strategic focus.
By addressing challenges, leveraging opportunities, and maintaining growth momentum, Sotera Health aims to sustain its positive performance trajectory and investor appeal in the competitive landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sotera Health Company (NASDAQ:SHC ) Q1 2022 Results Conference Call May 5, 2022 9:00 AM ET Company Participants Michael Petras - Chairman and CEO Scott Leffler - CFO Conference Call Participants Sean Dodge - RBC Capital Luke Sergott - Barclays Matt Miksic - Credit Suisse Patrick Donnelly - Citi Matthew Mishan - KeyBanc Dave Windley - Jefferies Michael Polark - Wolfe Research Casey Woodring - JPMorgan Operator Good morning. This is Joe and welcome to Sotera Health's First Quarter 2022 Results Call.

Sotera Health Company (SHC) CEO Michael Petras on Q1 2022 Results - Earnings Call Transcript

Sotera Health Company (SHC) delivered earnings and revenue surprises of 15.79% and 2.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sotera Health Company (SHC) Q1 Earnings and Revenues Surpass Estimates

CLEVELAND, May 05, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2022.

Sotera Health Reports First-Quarter 2022 Results

Sotera Health Company (SHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Sotera Health Company (SHC) is Poised to Beat Earnings Estimates Again

Sotera Health Company (SHC) CEO Michael Petras on Q4 2021 Results - Earnings Call Transcript

CLEVELAND, March 01, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2021.

Sotera Health Reports Fourth-Quarter and Full-Year 2021 Results; Provides 2022 Outlook

New Nelson Labs Mark offers transparency and confidence in product testing New Nelson Labs Mark offers transparency and confidence in product testing

Nelson Labs Launches Verification Program to Help Consumers Identify Properly Tested Masks and Respirators

CLEVELAND, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today is providing an update on the Company's accomplishments and key growth drivers, as well as the current market dynamics related to its businesses. At the 40th Annual J.P. Morgan Healthcare Conference, Chairman and Chief Executive Officer Michael B. Petras, Jr. will highlight Sotera Health's long-term organic and inorganic growth roadmap, addressable markets, and its environmental, social and governance (“ESG”) program.

Sotera Health Chairman and CEO Presents at 40th Annual J.P. Morgan Healthcare Virtual Conference

CLEVELAND, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 am Eastern. In his presentation, Mr. Petras will provide an update on Sotera Health's businesses. Sotera Health management, including Chief Financial Officer Scott Leffler, will participate in one-on-one meetings with investors during the conference.

Sotera Health to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

Sotera Health Company (SHC) CEO Michael Petras on Q3 2021 Results - Earnings Call Transcript

Investors weren't happy with the company's full-year guidance.

Why Sotera Health Stock Is Falling Today

CLEVELAND, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third quarter and nine months ended September 30, 2021 before market open on Wednesday, November 10, 2021. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.

Sotera Health Announces Q3 2021 Earnings Release Date

SALT LAKE CITY and OAK BROOK, Ill., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Nelson Labs and Sterigenics Germany GmbH, global leaders in comprehensive laboratory testing and sterilization services, announced today the opening of a newly expanded, center of excellence for microbiological laboratory testing as well as increased sterilization capacity in their Wiesbaden, Germany facilities. This expansion will address the significantly increased demand for these services by the medical device and pharmaceutical industries.

Nelson Labs® and Sterigenics® Open State-of-the-Art Laboratory and Expand Sterilization Facilities to Meet Growing Customer Demand in Europe

Sotera Health Company (SHC) CEO Michael Petras on Q2 2021 Results - Earnings Call Transcript

Sotera Health Company (SHC) CEO Michael Petras on Q1 2021 Results - Earnings Call Transcript

CLEVELAND, May 13, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2021.

Sotera Health Reports First-Quarter 2021 Results

OAK BROOK, IL, March 10, 2021 (GLOBE NEWSWIRE) -- Sterigenics S.A.S., a subsidiary of Sotera Health and a global leader in comprehensive sterilization services, announces the expansion of its ethylene oxide (EO) facility located in Rantigny, France to increase European sterilization capacity. The expansion increases the Rantigny facility's total sterilization throughput and diversifies its capabilities with the addition of a 32-pallet chamber. “Local and regional demand for contract sterilization services has been increasing to meet healthcare needs,” said Pontus Rundstrom, Vice President, Operations EMEAA. “The additional capacity at Rantigny shows our commitment to our sterilization customers by helping to get their products into the market in a fast, flexible and reliable way.”

Sterigenics Announces Expansion of Rantigny Facility to Increase European Sterilization Capacity

CLEVELAND, March 09, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2020.

Sotera Health Reports Fourth-Quarter and Full-Year 2020 Results; Provides 2021 Outlook

CLEVELAND, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that it has closed on an amendment repricing its First Lien Term Loan facility. The interest rate spread over LIBOR on the facility was reduced from 450 basis points to 275 basis points, and the facility's LIBOR floor was reduced from 100 basis points to 50 basis points. The changes result in an effective reduction in current interest rates of 2.25%.

Sotera Health Announces Successful Repricing of its First Lien Term Loan Facility

CLEVELAND, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that it has paid down over $1.1 billion of indebtedness with the proceeds of its recent initial public offering. Sotera Health used the proceeds of the offering to pay down $341 million of its first lien term loan at the end of November, as well as to redeem all of the $770 million aggregate principal amount of its senior secured second lien notes on December 14 at a redemption price of 102% of principal (plus accrued and unpaid interest, which was paid with cash on hand).

Sotera Health Announces Debt Pay Down and Expansion of Revolving Credit Facility

CLEVELAND, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) today announced the closing of its initial public offering (“IPO”) of 53,590,000 shares of its common stock at a public offering price of $23.00 per share, for gross proceeds of approximately $1.2 billion, before deducting underwriting discounts and commissions and offering expenses.

Sotera Health Announces Closing of Initial Public Offering

Sotera Health is a dominant player in sterilization of medical products. The company's products and services are very much in demand, as the company operates in a market which is hard to enter.

Sotera Health: High Expectations For This Medical Products Sterilization Play

Sotera Health raised $1.1 billion with an initial public offering for the provider of medical sterilization, lab testing and advisory services. The Sotera IPO will begin trading Friday.

Sotera Health IPO Prices At High End Of Range; Shares Surge

Shares of Sotera Health Co. started their public life with a rally Friday, as the first trade of the sterilization and lab-testing services provider's stock was 17.4% above the initial-public-offering price. The IPO priced late Thursday at $23 a share, at the top of the expected range.

Sotera Health's stock rallies out of the gate to lift the market cap above $7 billion

Shares of Sotera Health Co. are set to start trading Friday, after the Ohio-based sterilization and lab-testing services provider's initial public offering priced at the high end of the expected range. The company said late Thursday that its 46.6 million-share offering priced at $23.00 a share, compared with expectations of between $20 to $23, as the company raised $1.07 billion in the IPO.

News for Sotera Health Stock (SHC)